Focus: Healios is a Japan-based stem cell regenerative medicine biotech focused on cell therapy platforms, particularly the MultiStem® program targeting critical care and cardiovascular indications. The company operates as a mid-cap biotech with a diversified pipeline spanning stroke, cardiac, pulmonary, and trauma applications.
Profile data last refreshed 31m ago · AI intelligence enriched 2mo ago
Growing — net +6 jobs in 30d
6 jobs added vs 0 removed. Steady team buildout.
Best suited for early-stage biotech specialists willing to bet on cell therapy platform potential, but limited hiring visibility creates significant uncertainty about career trajectory and organizational stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Healios
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Healios's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles